Ftse Mib
35.108,74
0,49%
DAX
20.329,94
-0,10%
S&P 500
5.918,25
0,16%
NASDAQ
19.478,88
-0,06%
Bitcoin
93.926,50
-1,19%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Bicycle Therapeutics PLC (BCYC) Bicycle Therapeutics PLC (BCYC) Notizie

BCYC

Bicycle Therapeutics (BCYC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BCYC
DataOraFonteTitoloSimboloCompagnia
07/01/202501:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCYCBicycle Therapeutics PLC
06/01/202518:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BCYCBicycle Therapeutics PLC
03/01/202522:05Business WireBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCYCBicycle Therapeutics PLC
19/12/202421:47Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:BCYCBicycle Therapeutics PLC
13/12/202415:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCYCBicycle Therapeutics PLC
13/12/202400:30Business WireBicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene AmplificationNASDAQ:BCYCBicycle Therapeutics PLC
10/12/202413:00Business WireBicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology ExpertsNASDAQ:BCYCBicycle Therapeutics PLC
25/11/202423:30Business WireBicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program UpdateNASDAQ:BCYCBicycle Therapeutics PLC
14/11/202422:32Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BCYCBicycle Therapeutics PLC
12/11/202413:00Business WireBicycle Therapeutics to Participate in the Jefferies London Healthcare ConferenceNASDAQ:BCYCBicycle Therapeutics PLC
31/10/202412:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCYCBicycle Therapeutics PLC
31/10/202412:00Business WireBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial ResultsNASDAQ:BCYCBicycle Therapeutics PLC
23/10/202413:00Business WireBicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation RadiopharmaceuticalsNASDAQ:BCYCBicycle Therapeutics PLC
16/10/202413:00Business WireBicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 CongressNASDAQ:BCYCBicycle Therapeutics PLC
14/09/202409:00Business WireBicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024NASDAQ:BCYCBicycle Therapeutics PLC
21/08/202413:00Business WireBicycle Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:BCYCBicycle Therapeutics PLC
06/08/202423:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BCYCBicycle Therapeutics PLC
06/08/202413:05Business WireBicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial ResultsNASDAQ:BCYCBicycle Therapeutics PLC
22/07/202413:00Business WireBicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024NASDAQ:BCYCBicycle Therapeutics PLC
18/06/202422:14Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:BCYCBicycle Therapeutics PLC
23/05/202423:05Business WireBicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual MeetingNASDAQ:BCYCBicycle Therapeutics PLC
23/05/202413:00Business WireBicycle Therapeutics Announces $555 Million Private Placement Equity FinancingNASDAQ:BCYCBicycle Therapeutics PLC
02/05/202413:00Business WireBicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsNASDAQ:BCYCBicycle Therapeutics PLC
24/04/202416:05Business WireBicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual MeetingNASDAQ:BCYCBicycle Therapeutics PLC
02/04/202413:00Business WireBicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:BCYCBicycle Therapeutics PLC
05/03/202422:35Business WireBicycle Therapeutics to Present at the AACR Annual Meeting 2024NASDAQ:BCYCBicycle Therapeutics PLC
21/02/202422:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BCYCBicycle Therapeutics PLC
20/02/202413:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BCYCBicycle Therapeutics PLC
20/02/202413:05Business WireBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:BCYCBicycle Therapeutics PLC
14/02/202422:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BCYCBicycle Therapeutics PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BCYC

La tua Cronologia

ASX
KLA
Kirkland Lake Gold
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network